Circulating tumor DNA (ctDNA) dynamics in colorectal cancer (CRC) patients with molecular residual disease: Updated analysis from GALAXY stu

Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE

24-month GALAXY analysis

Natera's Human Rights Policy

Environmental Health and Safety Policy

Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer

Cohen S, Kasi P, Aushev VN, et al.

Tumor mutational signatures in early-onset versus average-onset colorectal cancer

Lander EM, Rivero-Hinojosa S, Aushev VN, et al.

Kinetics of postoperative circulating cfDNA and impact on MRD detection rates in patients with resected stage I-III CRC

Cohen SA, Kasi PM, Aushev VN, et al.

Natera's 2022 ESG & Social Responsibility Report

Increases in Donor-Derived Cell-Free DNA Prior to Biopsy Proven Rejection in Kidney Transplant

A presentation by Jonathan Bromberg, MD, PhD, of the University of Maryland School of Medicine from ATC2023.

Natera's Environmental Policy

Nominating, Corporate Governance and Compliance Committee Charter

Code of Conduct

Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair d

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Effic

DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy

Signatera Breast Cancer Data Sheet

Signatera Patient Test Sample Report

Natera’s ESG commitment